18F GP1

Drug Profile

18F GP1

Alternative Names: 18F-GPI; 18F-GP1; F18-GP1; GP1-18F; GP1-F18

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Developer Piramal Imaging; University of Zurich
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Ionising radiation emitters; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Thrombosis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in Thrombosis(Diagnosis) in Switzerland (Parenteral, Injection)
  • 08 May 2017 University of Zurich and Piramal Imaging terminate a phase I trial for Thrombosis (Diagnosis) in Switzerland (NCT02469376) prior to May 2017
  • 14 Nov 2014 18F GP1 is available for licensing as of 14 Nov 2014. http://www.piramal.com/imaging/about-us/business-dev-licensing.html
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top